MetaCap

MoonLake Immunotherapeutics (MLTX) vs Savara (SVRA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

MoonLake Immunotherapeutics (MLTX) has outperformed Savara (SVRA) over the past year, losing 12.6% versus a loss of 13.4%. Over five years, SVRA leads with a +270.4% price change compared with +12.2% for MLTX. MoonLake Immunotherapeutics is the larger company by market cap ($942.1 million vs $939.9 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MLTX-12.63%SVRA-13.41%
+80%+25%-30%
Nov 21, 20251 yearNov 20, 2026
MLTX+11.59%SVRA+294.44%
+570%+245%-79%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MLTX versus SVRA key metrics
MetricMLTXSVRA
Share price$11.07$4.26
Market cap$942.13M$939.86M
1-day change+0.36%-18.23%
YTD return-16.01%-29.35%
1-year return-12.63%-13.41%
5-year return+12.16%+270.43%
EPS (TTM)$-3.66$-0.60
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-227.32M$-118.84M
52-week high$23.29$7.01
52-week low$9.46$4.00
Distance from 52-week high-52.47%-39.19%
Analyst consensusbuystrong_buy
Avg. price target upside+173.62%+159.62%
Average volume1.64M2.79M
Shares outstanding85.11M220.62M
Employees13070
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About MoonLake Immunotherapeutics

MLTX stock →

MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis.

Health Care · Biotechnology: Pharmaceutical Preparations · 130 employees

About Savara

SVRA stock →

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 70 employees

MLTX vs SVRA FAQ

Which is bigger, MoonLake Immunotherapeutics or Savara?

MoonLake Immunotherapeutics (MLTX) is larger, with a market capitalization of $942.13M compared with $939.86M for Savara (SVRA).

Which stock has performed better over the past year, MLTX or SVRA?

MLTX returned -12.63% over the past 12 months, compared with -13.41% for SVRA (price return, excluding dividends). Past performance does not predict future results.

Are MoonLake Immunotherapeutics and Savara in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons